A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding [EXTENSION OF 700230234]

Trial Profile

A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding [EXTENSION OF 700230234]

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Uterine haemorrhage; Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms PEARLext2
  • Sponsors PregLem
  • Most Recent Events

    • 15 Aug 2015 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
    • 18 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top